AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02283216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noise sound stimulation (Tucker-Davis Technologies)
Description: Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
Study NCT02283216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body electrical stimulation (Digitimer device)
Description: Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
Study NCT02283216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation (Magstim)
Description: Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
Study NCT00864500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate 0.05% lotion, single exposure
Description: A: Experimental Subjects received Alpharma USPD, Inc formulated products
Study NCT00864500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobex TM 0.05% Lotion, single exposure
Description: B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
Study NCT00273364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Therapy
Description: After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
Study NCT00273364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment with a conventional drug
Description: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
Study NCT02023723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy Drink
Description: 16oz energy drinks - 2 consumed within 60 minutes
Study NCT02023723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: 16oz energy drinks - 2 consumed within 60 minutes
Study NCT02023723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: 16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
Study NCT04376645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Setback with maxillary impaction
Description: Occlusal bite force will be measured after surgery to correct vertical disproportions
Study NCT04376645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular setback only
Description: Occlusal bite force will be measured after surgery without changing vertical disproportions.
Study NCT03154619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% TR 987
Description: TR 987 0.1%
Study NCT03154619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
Study NCT01007461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide (Na2S) for Injection
Description: IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started > 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
Study NCT01007461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
Study NCT01132521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
Study NCT01132521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
Study NCT00445614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of trout on CVD risk markers and plasma proteome
Study NCT00445614 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Effects of trout on CVD risk markers and plasma proteome
Study NCT04535596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week long strength training exercises for knee
Study NCT03040258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-E-PALS-Pilot
Description: Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
Study NCT03132597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: six weeks of 2 hours class of mindfulness training and orientations for home training
Study NCT03318614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics M-63
Description: B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
Study NCT03318614 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No probiotic intervention was given to the control group for three months.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm.
Study NCT03003520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
Study NCT03794765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
Study NCT03794765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
Study NCT03794765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Similar placebo infusion
Study NCT01744444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
Study NCT01744444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
Study NCT01837316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg
Description: First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
Study NCT01837316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: First strip: Inhalation powder of lactose
Study NCT01332149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.
Study NCT01332149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched with pregabalin
Description: Subject will take placebo matched with pregabalin twice a day.
Study NCT01701466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aveeno cream
Description: Twice a day
Study NCT01701466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aveeno cream
Description: Twice a day
Study NCT01701466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamazine cream
Description: Twice a day, when there is dry desquamation
Study NCT01701466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flamazine cream
Description: Twice a day, when there is dry desquamation
Study NCT01701466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeoVIDERM cream
Description: Three times a day
Study NCT00218062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Amphetamine 30mg
Study NCT00218062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Amphetamine 60mg
Study NCT00218062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Study NCT00218062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Study NCT00218062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
Study NCT00218062 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
Study NCT00218062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02023723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Control
Description: 16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
Study NCT02642991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phenacite
Description: contact lens
Study NCT02642991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenacite
Description: contact lens
Study NCT02642991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens
Study NCT02642991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: contact lens
Study NCT01853969 — intervention group
Intervention type: OTHER
Intervention: Typing assessment
Study NCT03515681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
Study NCT00123981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-Pump Coronary Artery Bypass Grafting
Study NCT00123981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-Pump Coronary Artery Bypass Grafting
Study NCT00422565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor, Medtronic
Description: Zotarolimus-eluting stent
Study NCT00422565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher, Cordis
Description: Sirolimus-eluting stent
Study NCT00422565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte, Boston Scientific
Description: Paclitaxel-eluting stent
Study NCT01088516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC
Description: Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
Study NCT03085927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Music Engagement
Description: Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
Study NCT03085927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Storybooks
Description: Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
Study NCT03475160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate vaginal suppositories
Description: Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
Study NCT03475160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal suppositories
Description: Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
Study NCT03475160 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Uterine artery Doppler before treatment
Description: Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
Study NCT03475160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery Doppler before treatment
Description: Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
Study NCT03475160 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Uterine artery Doppler after treatment
Description: Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
Study NCT03475160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery Doppler after treatment
Description: Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
Study NCT01313234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Theory based education and systematic daily assessment
Study NCT02787356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS Lidocaine 5%; generic
Description: TDS Lidocaine 5%; generic
Study NCT02787356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS Lidocaine 5%; RLD
Description: TDS Lidocaine 5%; RLD
Study NCT03176810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT is used to guide PCI.
Study NCT03176810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Angiography is used to guide PCI.
Study NCT02694991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipatasertib
Description: Given PO
Study NCT03853707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03853707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03853707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03853707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03853707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03509701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VZV-specific antibody response from blood
Description: Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
Study NCT01697384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histrelin acetate
Description: 52 week implant
Study NCT03111992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD1 antibody
Study NCT03111992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJM112
Description: Anti-IL-17A antibody
Study NCT03111992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: Oral small molecule SMAC-mimetic
Study NCT04442594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality session
Description: The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.
Study NCT04442594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality session
Description: The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.
Study NCT01529645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Description: Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.